ArticleMolecular biology reports2026
Integrated bioinformatic and experimental analyses identify Lumican as a key regulator of LIPUS-induced osteogenesis through Integrin β1/FAK/ERK signaling.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLow-intensity pulsed ultrasound (LIPUS) is an established noninvasive therapy for bone regeneration; however, the extracellular matrix (ECM)-associated mechanisms underlying LIPUS-mediated mechanotransduction remain poorly understood. This study aimed to investigate the role of Lumican, an ECM proteoglycan, in LIPUS-induced osteogenic differentiation and its relationship with Integrin β1 signaling.
methodsTranscriptomic analysis of the GEO dataset GSE45487 was performed to identify LIPUS-responsive genes and signaling pathways in MC3T3-E1 cells. Cell proliferation, alkaline phosphatase activity, matrix mineralization, quantitative real-time PCR, and Western blot analyses were conducted to evaluate osteogenic differentiation. Lumican and Integrin β1 expression were silenced using siRNA to investigate their functional roles in LIPUS-mediated osteogenesis.
resultsLIPUS significantly promoted MC3T3-E1 cell proliferation, osteogenic gene expression, alkaline phosphatase activity, and extracellular matrix mineralization. Bioinformatic analyses identified ECM-related biological processes and ECM-receptor interaction pathways as major transcriptional responses to LIPUS stimulation, with Lumican emerging as a highly connected hub gene. LIPUS markedly increased Lumican expression, whereas Lumican knockdown attenuated osteogenic differentiation and mineralization. Mechanistically, Lumican deficiency suppressed LIPUS-induced Integrin β1 expression and the phosphorylation of FAK and ERK. Furthermore, siRNA-mediated silencing of Integrin β1 recapitulated the inhibitory effects of Lumican knockdown and significantly impaired the expression of osteogenic markers.
conclusionsLumican mediates the pro-osteogenic effects of LIPUS through activation of the Integrin β1/FAK/ERK signaling pathway. These findings identify a previously unrecognized ECM-centered mechanotransduction mechanism underlying LIPUS-induced osteogenesis and highlight Lumican as a potential therapeutic target for ultrasound-mediated bone regeneration.
Indexed as
Identifiers
42579159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.